Formulation for the prevention of cardiovascular disease
View Patent ↗This invention relates to a method for the prevention of cardiovascular disease, a formulation for the prevention of cardiovascular disease, the use of specified active principals for the manufacture of such a formulation for use in the method and to a method of preparing said formulation. The formulation of the present invention is a combination of active principals for use in the prevention of cardiovascular disease, notably ischaemic heart disease (including heart attacks) and stroke among the general adult population.
1. A method for reducing the risk of cardiovascular disease comprising administering simultaneously, separately or sequentially to an individual with an unmeasured, or if measured normal blood pressure, active principals comprising at least two blood pressure lowering agents, each selected from a different physiological mode of action selected from a diuretic, a beta blocker, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, and a calcium channel blocker, and at least one active principal from the following three categories:
i) at least one lipid-regulating agent;
ii) at least one serum homocysteine lowering agent; and
iii) at least one platelet function altering agent.
2. A method for reducing the risk of cardiovascular disease comprising administering simultaneously, separately or sequentially, active principals comprising at least two blood pressure lowering agents, each selected from a different physiological mode of action selected from a diuretic, a beta blocker, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, and a calcium channel blocker, and at least one active principal from the following three categories:
i) at least one lipid-regulating agent;
ii) at least one serum homocysteine lowering agent; and
iii) at least one platelet function altering agent,
to an individual with an unmeasured, or if measured normal, level of each of the risk factors of cardiovascular disease selected from blood pressure, serum cholesterol, and serum homocysteine that are altered by the active principals administered to the patient.
3. The method according to claim 1 or 2 , wherein the dose of each blood pressure lowering agent is below the lower therapeutic dosage for the blood pressure lowering agent.
4. The method according to claim 1 or 2 , wherein active principals selected from at least two of the following three categories are administered:
i) at least one lipid-regulating agent,
ii) at least one serum homocysteine lowering agent, and
iii) at least one platelet function altering agent.
5. The method according to claim 1 or 2 , wherein the active principals are administered to an individual above a predetermined age.
6. The method according to claim 1 or 2 , wherein the method is applied to an individual who has not previously been diagnosed as having had the clinical symptoms of cardiovascular disease.
7. The method according to claim 1 or 2 , wherein the active principals are administered simultaneously in a single dosage form.
8. The method according to claim 1 or 2 , wherein the dosage of at least one of the active principals is selected to maximize the potency to hazard ratio, attaining a near maximal reduction of risk of cardiovascular disease whilst minimizing undesirable side effects.
9. The method according to claim 1 , wherein the dose of a blood pressure lowering agent is below the lower therapeutic dosage for the blood pressure lowering agent to further maximize the potency to hazard ratio.
10. The method according to claim 1 or 2 , wherein the dose of a blood pressure lowering agent is about half the lower therapeutic dosage for the blood pressure lowering agent.
11. The method according to claim 1 or 2 , comprising:
about 12.5 mg hydrochlorothiazide, about 25 mg atenolol, and about 5 mg enalapril as blood pressure lowering agents,
about 10 mg atorvastatin as a lipid-regulating agent,
about 75 mg aspirin as a platelet function altering agent, and
about 0.8 mg folic acid as a serum homocysteine lowering agent;
wherein each specified dose is the daily dose.
12. The method according to claim 1 or 2 , comprising:
about 12.5 mg hydrochlorothiazide, about 25 mg atenolol, and about 5 mg enalapril as blood pressure lowering agents,
about 10-20 mg simvastatin as a lipid-regulating agent,
about 75 mg aspirin as a platelet function altering agent, and
about 0.8 mg folic acid as a serum homocysteine lowering agent;
wherein each specified dose is the daily dose.
13. The method according to claim 1 or 2 , wherein the risk of cardiovascular disease is reduced by at least 80%.